Organon & Co. (OGN)

Organon & Co.'s stock price has significantly declined over the past year. The share price decreased by 56.34% between November 25, 2024, and November 24, 2025, and was down 50.98% over the past 12 months. In Q3 2025, Organon exceeded market revenue expectations with a 1.3% year-on-year sales increase to $1.60 billion, but full-year revenue guidance was slightly below analysts' estimates. The resignation of CEO Kevin Ali due to improper wholesaler sales practices impacted the stock. The US FDA approved POHERDY, the first PERJETA biosimilar in the US, and Organon agreed to divest its JADA System for up to $465 million to Laborie.

There is some indication of demand seasonality for certain Organon products. Respiratory products can experience increased demand associated with seasonally poor air quality. The Women's Health segment's revenue in Q1 2024 was influenced by customer purchasing patterns related to the timing of U.S. list-price adjustments and the timing of tenders in international markets, suggesting potential cyclicality or seasonality in purchasing behavior.

Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, operating within the Pharmaceuticals sector. Its diverse portfolio includes over 60 medicines and products, including contraception, fertility drugs, immunology and oncology treatments, cholesterol-modifying medicines, hypertension treatments, respiratory products, dermatology products, bone health products, and non-opioid pain management products.

Organon & Co. has a significant global presence, operating in over 140 markets with direct sales in 58. The company is headquartered in Jersey City, New Jersey, U.S. While manufacturing occurs outside the U.S., approximately one-third of its revenue is generated from the U.S. Manufacturing facilities are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the UK.

Organon's brand reputation was significantly affected by the resignation of its CEO, Kevin Ali, following an internal investigation into improper wholesaler sales practices, which negatively impacted public perception and investor confidence.

Organon & Co.'s ownership is predominantly held by institutional investors, who collectively own approximately 83.09% to 92% of the company's stock. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., iShares Core S&P Small-Cap ETF, Massachusetts Financial Services Co /ma/, and State Street Corp. Individual investors and company insiders hold smaller portions, with insiders holding around 0.33% to 0.5% of shares.